Teva Total Stockholder Equity vs Net Working Capital Analysis
TEVA Stock | USD 13.98 0.10 0.71% |
Teva Pharma financial indicator trend analysis is much more than just breaking down Teva Pharma Industries prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Teva Pharma Industries is a good investment. Please check the relationship between Teva Pharma Total Stockholder Equity and its Net Working Capital accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharma Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.
Total Stockholder Equity vs Net Working Capital
Total Stockholder Equity vs Net Working Capital Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Teva Pharma Industries Total Stockholder Equity account and Net Working Capital. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between Teva Pharma's Total Stockholder Equity and Net Working Capital is -0.61. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Net Working Capital in the same time period over historical financial statements of Teva Pharma Industries, assuming nothing else is changed. The correlation between historical values of Teva Pharma's Total Stockholder Equity and Net Working Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of Teva Pharma Industries are associated (or correlated) with its Net Working Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Working Capital has no effect on the direction of Total Stockholder Equity i.e., Teva Pharma's Total Stockholder Equity and Net Working Capital go up and down completely randomly.
Correlation Coefficient | -0.61 |
Relationship Direction | Negative |
Relationship Strength | Weak |
Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Net Working Capital
Most indicators from Teva Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Teva Pharma Industries current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharma Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. At present, Teva Pharma's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 40.5 B, whereas Tax Provision is forecasted to decline to (7.3 M).
2021 | 2023 | 2024 (projected) | Interest Expense | 1.1B | 1.0B | 1.1B | Depreciation And Amortization | 1.3B | 1.2B | 667.3M |
Teva Pharma fundamental ratios Correlations
Click cells to compare fundamentals
Teva Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Teva Pharma fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 57.5B | 50.6B | 47.7B | 44.0B | 43.5B | 26.4B | |
Short Long Term Debt Total | 27.3B | 26.4B | 23.5B | 21.6B | 20.2B | 21.2B | |
Other Current Liab | 890M | 931M | 903M | 6.0B | 1.1B | 1.6B | |
Total Current Liabilities | 13.7B | 13.2B | 11.0B | 11.5B | 12.2B | 6.5B | |
Total Stockholder Equity | 14.0B | 10.0B | 10.3B | 7.9B | 7.5B | 9.9B | |
Property Plant And Equipment Net | 7.0B | 6.9B | 6.5B | 6.2B | 6.1B | 3.2B | |
Net Debt | 25.4B | 24.2B | 21.3B | 18.8B | 16.9B | 17.8B | |
Retained Earnings | (7.0B) | (10.9B) | (10.5B) | (12.9B) | (13.5B) | (12.9B) | |
Cash | 2.0B | 2.2B | 2.2B | 2.8B | 3.2B | 3.4B | |
Non Current Assets Total | 44.0B | 37.6B | 35.1B | 32.0B | 31.0B | 18.7B | |
Non Currrent Assets Other | 591M | 538M | 515M | 441M | 462M | 594.6M | |
Cash And Short Term Investments | 2.0B | 2.2B | 2.2B | 2.8B | 3.2B | 3.4B | |
Net Receivables | 5.7B | 4.6B | 4.5B | 3.7B | 3.4B | 3.0B | |
Common Stock Shares Outstanding | 1.1B | 1.1B | 1.1B | 1.1B | 1.1B | 777.0M | |
Liabilities And Stockholders Equity | 57.5B | 50.6B | 47.7B | 44.0B | 43.5B | 26.4B | |
Non Current Liabilities Total | 28.7B | 26.4B | 25.4B | 23.8B | 23.1B | 24.3B | |
Inventory | 4.4B | 4.4B | 3.8B | 3.8B | 4.0B | 2.4B | |
Other Current Assets | 434M | 710M | 967M | 549M | 505M | 914.4M | |
Other Stockholder Equity | 23.2B | 23.3B | 23.4B | 23.6B | 23.7B | 24.9B | |
Total Liab | 42.4B | 39.6B | 36.4B | 35.3B | 35.4B | 37.1B | |
Total Current Assets | 13.5B | 13.0B | 12.6B | 12.1B | 12.5B | 7.7B | |
Short Term Debt | 2.3B | 3.2B | 1.4B | 2.1B | 1.7B | 1.3B | |
Intangible Assets | 11.2B | 8.9B | 7.5B | 6.3B | 5.4B | 4.7B | |
Accounts Payable | 1.7B | 1.8B | 1.7B | 1.9B | 2.6B | 2.1B | |
Accumulated Other Comprehensive Income | (2.3B) | (2.4B) | (2.7B) | (2.8B) | (2.7B) | (2.6B) | |
Other Liab | 3.7B | 3.2B | 3.4B | 4.4B | 5.1B | 5.3B | |
Other Assets | 2.1B | 1.1B | 1M | (1M) | 1.9B | 950K | |
Long Term Debt | 24.6B | 22.7B | 21.6B | 19.1B | 18.2B | 12.5B | |
Property Plant Equipment | 6.4B | 6.3B | 6.0B | 6.2B | 7.1B | 4.8B | |
Current Deferred Revenue | 8.7B | 7.3B | 7.0B | 1.5B | 6.9B | 7.3B | |
Good Will | 24.8B | 20.6B | 20.0B | 17.6B | 17.2B | 17.7B | |
Property Plant And Equipment Gross | 6.4B | 6.9B | 6.5B | 6.2B | 11.8B | 12.4B | |
Short Long Term Debt | 2.3B | 3.2B | 1.4B | 2.1B | 1.7B | 2.6B | |
Net Tangible Assets | (22.1B) | (19.5B) | (17.2B) | (16.0B) | (14.4B) | (15.1B) |
Teva Pharma Investors Sentiment
The influence of Teva Pharma's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Teva. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Teva Pharma's public news can be used to forecast risks associated with an investment in Teva. The trend in average sentiment can be used to explain how an investor holding Teva can time the market purely based on public headlines and social activities around Teva Pharma Industries. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Teva Pharma's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Teva Pharma's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Teva Pharma's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Teva Pharma.
Teva Pharma Implied Volatility | 73.94 |
Teva Pharma's implied volatility exposes the market's sentiment of Teva Pharma Industries stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Teva Pharma's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Teva Pharma stock will not fluctuate a lot when Teva Pharma's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Teva Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Teva Pharma's short interest history, or implied volatility extrapolated from Teva Pharma options trading.
Currently Active Assets on Macroaxis
When determining whether Teva Pharma Industries offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Teva Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Teva Pharma Industries Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Teva Pharma Industries Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharma Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Complementary Tools for Teva Stock analysis
When running Teva Pharma's price analysis, check to measure Teva Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Teva Pharma is operating at the current time. Most of Teva Pharma's value examination focuses on studying past and present price action to predict the probability of Teva Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Teva Pharma's price. Additionally, you may evaluate how the addition of Teva Pharma to your portfolios can decrease your overall portfolio volatility.
Equity Valuation Check real value of public entities based on technical and fundamental data | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Teva Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teva Pharma. If investors know Teva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teva Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.4 | Earnings Share (0.50) | Revenue Per Share 14.161 | Quarterly Revenue Growth 0.148 | Return On Assets 0.0454 |
The market value of Teva Pharma Industries is measured differently than its book value, which is the value of Teva that is recorded on the company's balance sheet. Investors also form their own opinion of Teva Pharma's value that differs from its market value or its book value, called intrinsic value, which is Teva Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teva Pharma's market value can be influenced by many factors that don't directly affect Teva Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Teva Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teva Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.